ESOMAR-certified Future Market Insights (FMI) has recently published an exhaustive yet unbiased analysis of the global Gaucher and Pompe disease ERT market providing insights on key growth trends through 2030.As the global burden of genetic disorders such as Gaucher disease, Fabry disease, Pompe disease and other ab.
The Gaucher and Pompe Disease ERT Market is anticipated to record a positive growth trajectory, despite facing a glitch in the initial months of COVID-19, due to rising orphan drug status designation to several drug candidates by the FDA. The market is further growing due to surge in number of partnerships and colla.